ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODY AGAINST HUMAN ROR1, AND USE FOR THE SAME

• Main Authors: OH, JI HYE, JUNG, JINWON, EOM, JAEHYUN, LEE, HYEUN JOUNG, PARK, KYUNGJIN, BAEK, JU YUEL, YANG, YOUNG-JAE, YOU, JI-NA, HAN, NARA, SONG, DAEHAE, KIM, YONG ZU, YOO, JISEON, RYU, HYUN MIN, YEOM, DONGHOON, KIM, HYOUNG RAE, PARK, KYUNG EUN, LEE, BORA, KANG, DAE HYUCK, LEE, YANGSOON, HONG, YOUNGEUN, KIM, SUNG MIN, CHAE, JEIWOOK, KIM. JUHEE, AHN, JINHYUNG, SONG, HO YOUNG, LEE, JU YOUNG, PARK, MINJI, SUNG, BYUNGJE, PARK, YUN HEE, LEE, CHANG SUN
• Format: Patent
• Language: English; French
• Published: 11.03.2021
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same. La présente invention concerne de nouveaux conjugués anticorps-médicament (CAM) ciblant le ROR1, des métabolites actifs de tels CAM, des procédés de préparation de tels CAM, des utilisations de tels CAM dans le traitement et/ou la prévention de maladies, et des utilisations de tels CAM dans la production de médicaments pour le traitement et/ou la prévention de maladies, plus spécifiquement des maladies associées à une surexpression de ROR1, par exemple le cancer. Plus particulièrement, la présente invention concerne un conjugué anticorps-médicament comprenant un anticorps se liant au ROR1 ou un fragment de liaison d'antigène de celui-ci, et une composition pharmaceutique le comprenant.